Bihua Chen
Director at Erasca; 10% owner at MoonLake Immunotherapeutics; Chairperson and CEO at Helix Acquisition Corp. III. Based in Boston, Massachusetts.
- Rank
- 2971st of 14,644
- Companies held
- 1
- Largest holding
- MLTX, 100.0% of total
- Latest SEC filing
- Jul 1, 2026
- Listed but not counted
- $315M
What the $40.6M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| MoonLake Immunotherapeutics MLTX Class A Ordinary Shares | Through Helix Holdings LLC | 3,677,100 | $11.03 | $40.6M | 100.0% | Form 4, Jun 30, 2023 |
Share counts are the amounts Bihua Chen reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Bihua Chen's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Erasca ERAS Common Stock | Through Cormorant Global Healthcare Master Fund, LP Held by a company or fund the insider manages | 10,505,554 | $14.22 | $149M | — | Form 4, Jun 22, 2022 |
| MoonLake Immunotherapeutics MLTX Class A Ordinary Shares | Through Cormorant Asset Management, LP Held by a company or fund the insider manages | 4,927,100 | $11.03 | $54.3M | — | Form 4, Jun 30, 2023 |
| Helix Acquisition Corp. III HLXC Class B Ordinary Shares | Indirectly (see filing footnote) Held by a company or fund the insider manages | 4,252,500 | $10.30 | $43.8M | — | Form 4/A, Jan 22, 2026 |
| BridgeBio Oncology Therapeutics BBOT Common Stock | Via Master Fund Held by a company or fund the insider manages | 6,083,221 | $1.86 | $11.3M | — | Form 4, Jul 1, 2026 |
| BridgeBio Oncology Therapeutics BBOT Common Stock | Via Master Fund Held by a company or fund the insider manages | 5,952,356 | $1.86 | $11.1M | — | Form 4, Aug 11, 2025 |
| BridgeBio Oncology Therapeutics BBOT Common Stock | Via Fund V Held by a company or fund the insider manages | 5,010,332 | $1.86 | $9.3M | — | Form 4, Jul 1, 2026 |
| BridgeBio Oncology Therapeutics BBOT Common Stock | Via Fund III Held by a company or fund the insider manages | 4,879,995 | $1.86 | $9.1M | — | Form 4, Jul 1, 2026 |
| Helix Acquisition Corp. III HLXC Class A Ordinary Shares | Through Cormorant Global Healthcare Master Fund, LP Held by a company or fund the insider manages | 800,000 | $10.30 | $8.2M | — | Form 4/A, Jan 26, 2026 |
| BridgeBio Oncology Therapeutics BBOT Common Stock | Via Fund V Held by a company or fund the insider manages | 3,305,470 | $1.86 | $6.1M | — | Form 4, Aug 11, 2025 |
| Helix Acquisition Corp. III HLXC Class A Ordinary Shares | Indirectly (see filing footnote) Held by a company or fund the insider manages | 497,500 | $10.30 | $5.1M | — | Form 4/A, Jan 26, 2026 |
| BridgeBio Oncology Therapeutics BBOT Common Stock | Via Fund III Held by a company or fund the insider manages | 2,187,536 | $1.86 | $4.1M | — | Form 4, Aug 11, 2025 |
| BridgeBio Oncology Therapeutics BBOT Common Stock | Via Fund IV Held by a company or fund the insider manages | 1,905,046 | $1.86 | $3.5M | — | Form 4, Jul 1, 2026 |
Open-market trades, last 12 months
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 2968 | H. Lynn Moore Jr. President and CEO, Tyler Technologies. Plano, TX | $40.6M |
| 2969 | Richard G. Thornberry Chief Executive Officer, Radian Group. Wayne, PA | $40.6M |
| 2970 | Suzanne Helen Insider, Mohawk Industries. Dalton, GA | $40.6M |
| 2971 | Bihua Chen Director, Erasca. Boston, MA | $40.6M |
| 2972 | David Joseph Meyer Chairman, Titan Machinery. West Fargo, ND | $40.6M |
| 2973 | Christopher P. Marr CEO, CubeSmart. Boston, MA | $40.5M |
| 2974 | John Caplan Chief Executive Officer, Payoneer Global. New York, NY | $40.5M |
Other Erasca insiders
All ERAS insiders- Jonathan E. Lim$629MChairman & CEO. #390 overall
- Alexander W. Casdin$9.5MDirector. #9137 overall
- Wei Lin$4.5MChief Medical Officer. #5067 overall
Questions
How much stock does Bihua Chen own?
Bihua Chen holds $40,558,413 in listed stock based on SEC filings and current prices, mostly MoonLake Immunotherapeutics (MLTX). That ranks 2971st on the Stock Rich List.
Is this Bihua Chen's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Bihua Chen last buy or sell stock?
The most recent open-market trade on file is a purchase of 800,000 HLXC shares on Jan 26, 2026 at $10.00.